Despite carrying a “black box” warning – the Food and Drug Administration’s strictest advisory – for over four decades due to its association with life-threatening complications, the antibiotic clindamycin continues to be widely prescribed by dentists. A recent report from the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota revealed that dentists wrote more than 2.3 million prescriptions for clindamycin last year. The continued apply of the drug, even with known risks, raises questions about prescribing practices and the potential for increased rates of severe Clostridioides difficile (C. Diff) infections.
The concern surrounding clindamycin stems from its strong link to C. Diff, a bacterium that causes severe diarrhea, and colitis. The “black box” warning, first added in the 1980s, highlights this risk. C. Diff infections can range from mild to life-threatening, and are particularly dangerous for older adults and those with weakened immune systems. The CIDRAP report highlights the case of Dolores Hernandez Owens, who experienced severe complications after receiving a clindamycin prescription from her dentist, underscoring the real-world consequences of the drug’s use.
The Link Between Clindamycin and C. Diff
Clindamycin disrupts the natural balance of bacteria in the gut, creating an opportunity for C. Diff to flourish. This disruption isn’t unique to clindamycin; many antibiotics can cause similar effects. However, clindamycin is particularly strongly associated with C. Diff infection. The risk isn’t limited to patients who are already hospitalized or taking other medications; even otherwise healthy individuals can develop a C. Diff infection after taking clindamycin.
The Infectious Diseases Society of America (IDSA) has previously urged Bayer Corp. To withdraw enrofloxacin (Baytril) from the market due to concerns about antibiotic resistance, a related issue stemming from antibiotic overuse. Even as this case involved a different antibiotic and a different mechanism of harm, it illustrates the IDSA’s commitment to responsible antibiotic stewardship. The IDSA supported the Food and Drug Administration’s (FDA) proposal in 2000 to ban fluoroquinolones in poultry, citing evidence that it led to an increase in antibiotic-resistant Campylobacter in poultry, ultimately impacting human health.
Why is Clindamycin Still Prescribed?
Dentists often prescribe clindamycin to treat bacterial infections following dental procedures, such as extractions or root canals. While guidelines from organizations like the American Dental Association recommend antibiotics only in specific circumstances, the CIDRAP report suggests that many prescriptions may be unnecessary. The reasons for continued use are complex and likely include a desire to prevent post-operative infections, patient demand, and a lack of awareness of alternative treatment options.
The issue isn’t isolated to dentistry. Recent developments in pharmaceutical research and regulatory action demonstrate a dynamic landscape. The FDA recently approved milsaperidone (Bysanti) tablets for the treatment of schizophrenia and bipolar disorder, offering a new therapeutic option for patients with these conditions, as reported by MedPage Today. Meanwhile, Bayer has filed a lawsuit against Johnson & Johnson, alleging false advertising regarding a prostate cancer drug, highlighting the competitive pressures within the pharmaceutical industry, according to Stat.
Beyond Antibiotics: Other Health News
The broader health landscape is also seeing significant developments. Research suggests that tirzepatide, an ingredient in the diabetes drug Mounjaro, may reduce alcohol intake in rodents, as reported by The Hill. This finding, while preliminary, could have implications for the treatment of alcohol use disorder. Inflammatory bowel disease (IBD) research is also gaining momentum, with pharmaceutical companies racing to develop combination therapies for Crohn’s disease and ulcerative colitis, Stat News reports.
Supply chain issues continue to impact healthcare access, as evidenced by a current shortage of estrogen patches, affecting women undergoing menopause hormone therapy, according to CNN. Merck is also restructuring its pharmaceutical unit, creating a separate cancer business in anticipation of patent expirations on key drugs like Keytruda, as detailed by The Wall Street Journal. Advances in cardiology are also emerging, with research exploring the potential of fracturing mechanical heart valves to allow for subsequent valve-in-valve therapy, MedPage Today reports.
Globally, Zimbabwe is among the first countries to roll out lenacapavir, a long-acting HIV prevention drug, offering a potential turning point in the fight against HIV infection, according to the Associated Press.
The continued prescribing of clindamycin despite its known risks underscores the demand for greater antibiotic stewardship and a more nuanced understanding of the benefits and harms of antibiotic use. The FDA is currently considering extending the approval of the RSV vaccine Arexvy to include adults aged 50 to 59, potentially broadening protection against this respiratory virus.
The FDA will continue to monitor antibiotic prescribing patterns and evaluate new data on the risks and benefits of clindamycin. Patients should discuss the risks and benefits of any antibiotic with their dentist or physician and explore alternative treatment options when appropriate. Further research is needed to identify strategies to reduce unnecessary clindamycin prescriptions and minimize the risk of C. Diff infections.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
What are your thoughts on antibiotic prescribing practices? Share your comments below, and please share this article with anyone who might find it helpful.
